The addition of the targeted drug Avastin® (bevacizumab) to chemotherapy did not improve outcomes among women receiving preoperative chemotherapy for early stage breast cancer. The results of this Phase III clinical trial were presented at the 2010 San Antonio Breast …
Source: Breast Cancer News